Ojjaara (momelotinib) – New orphan drug approval
September 15, 2023 - GSK announced the FDA approval of Ojjaara (momelotinib), for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Top